Portal vein thrombosis in cirrhosis: Predictors of successful anticoagulation therapy

s / Digestive and Liver Disease 46S (2014) e129–e135 e133 management mean costs =16,440$ for patient). HCV etiology had a strong impact on post-LT survival (Hazard Ratio =1.59, 95% CI =1.22–2.09, p=0.0007). Using recent data on SOF efficacy and costs in the base-case scenario, 12-week pre-LT SOF therapy showed a median survival benefit of 3.1 QALYs, an ICER of 35,168$/QALY, and a NHB of 0.9 QALYs, whereas the ICER and NHB of a 24-week therapy were 52,527$/QALY and −0.2 QALY respectively. Conclusions: SOF used as pre-transplant therapy in HCV patients proved to be a cost-effective treatment strategy compared with post-LT SOC therapy. Conflict of interest: None declared. Disclosures: S. Fagiuoli acted as either Advisory Board Member or Speaker’s Bureau for: BMS, MSD, Gilead Sciences, Abvie, Roche, Janssen, Novartis, Grifols, Biotest, Kedrion, Bayer. Liver Transplantation NITp Working Group Luciano De Carlis (Surgery and Transplantation, Ospedale Niguarda Ca’ Granda, Milan, Italy), Michele Colledan (Gastroenterology and Transplantation Hepatology, Ospedali Riuniti, Bergamo, Italy), Giorgio Rossi (Liver Transplantation Unit, Fond, IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, Italy), Enzo Andorno (IRCCS San Martino, Genoa, Italy), Andrea Risaliti (Liver Transplant Unit, University of Udine, Udine, Italy), Vincenzo Mazzaferro (Liver Transplantation, IRCCS INT, Milan, Italy), Marco Vivarelli (Liver Transplantation Unit, Ancona Hospital, Ancona, Italy), Umberto Tedeschi (Liver Transplantation Unit, Verona Hospital, Verona, Italy), Davide Bitetto (Gastroenterology and Transplant Hepatology, Ospedale Papa Giovanni XXIII, Bergamo, Italy), Angelo Sangiovanni (Gastroenterology Unit, Maggiore Hospital Policlinico, Milan, Italy), Lucio Caccamo (Liver Transplantation Unit, Fond. IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, Italy), Daniele Neri (University of Padova, Padua, Italy), Giuseppe Piccolo (Fond, IRCCS Ca’ Granda OMP, Milan, Italy), Francesco Paolo Russo (University of Padova, Padua, Italy), Luciano Biti (Liver Transplantation Unit, Verona Hospital, Italy), Paolo Angeli (University of Padova, Padua, Italy), Vittorio Corno (Gastroenterology and Transplantation Hepatology, Ospedali Riuniti, Bergamo, Italy) http://dx.doi.org/10.1016/j.dld.2014.08.012 OC-09 TUMORIGENIC POTENTIAL OF CANCER STEM CELLS (CSCS) ISOLATED FROM HUMAN CHOLANGIOCARCINOMA (CCA) SUBTYPES IN CIRRHOTIC LIVER A. Torrice1 , G. Carpino2, A. Fraveto1, A. Renzi3, M.C. Bragazzi1, F. Giuliante4, A.M. Derose4, V. Cardinale1, R. Gentile1, P. Onori3, C. Napoletano5, A. Franchitto3, A. Cantafora1, G. D’Argenio6, N. Caporaso6, G. Grazi7, E. Gaudio3, D. Alvaro1 1 Medico-Surgical Sciences and Biotechnologies, Sapienza University of Rome, Rome, Italy 2 Health Science, University of Rome “Foro Italico”, Rome, Italy 3 SAIMLAL, Sapienza, University of Rome, Rome, Italy 4 Surgery, Hepatobiliary Unit, Catholic University of the Sacred Heart School of Medicine, Rome, Italy 5 Experimental Medicine, Sapienza University of Rome, Rome, Italy 6 Gastroenterology Unit, Department of Clinical and Experimental Medicine, Federico II University of Naples, Naples, Italy 7 Hepato-Biliary Surgery, Regina Elena National Cancer Institute, Rome, Italy Introduction: Two different forms of CCA has been considered. A pure mucin-secreting form (Mucin-CCA) located either intra or extra-hepatically and a Mixed-CCA form with a peripheral location. We previously identified different subpopulations of CCA CSCs, including epithelial (CD133+, LGR5+, EpCAM+),mesenchymal (CD90+) and quiescent (CD13+) CSCs. Aim: To evaluate the tumorigenic potential of different subpopulation of CSCs isolated from human Mucinand Mixed-CCAs. Methods: CSC subpopulations were immunoselected from human CCA samples (n=18 surgically resected patients) or from primary cultures. The tumorigenic potential of CSC subpopulations was tested either in vitro (spheroid formation), or in xenografts obtained by subcutaneous or intrahepatic injection in normal or cirrhotic (CCL4-induced) livers in SCID mice. In vitro, epithelial CSCs (CD133+, EpCAM+, LGR5+) formed a higher (p 80% (p<0.01). Conclusions: Heterogeneous CSC subpopulations were represented in human CCAs. They generate different type of cancers depending from the type of CSC and the microenvironment. Remarkably, we identified CSC subpopulations capable to reproduce highly invasive and undifferentiated human CCA (CD13+ and CD90+) when injected in mice cirrhotic livers. http://dx.doi.org/10.1016/j.dld.2014.08.013